BioNexus Gene Lab Corp (BGLC) — Institutional Holders, Q2 2026
3 institutional investment managers reported a BGLC position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $226.00. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
BGLC in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- Caitong International Asset Management , LtdNew · +1 sh+$2.00
Biggest sellers
- UBS Group AGTrimmed · -130 sh-$254.00
- WELLS FARGO & COMPANYSold out · -1 sh-$2.00
BGLC 13F holders ranked 1–3 of 3
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | UBS Group AG#1 · 101 sh | 101 | $197.00 | 0.00% | -56.3% |
| 2 | HRT FINANCIAL#2 · 14,283 sh | 14,283 | $27.00 | 0.00% | New |
| 3 | Caitong International Asset Management , Ltd#3 · 1 sh | 1 | $2.00 | 0.00% | New |
Funds that sold out of BGLC in Q2 2026 (1)
Held BGLC at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| WELLS FARGO & COMPANY1 sh | 1 | $2.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.